Anand Mahadevan

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Int J Radiat Oncol Biol Phys 81:1500-5. 2011
  2. ncbi Clinical outcome after hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, MA 02445, USA
    Comput Aided Surg 16:112-20. 2011
  3. ncbi Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Int J Radiat Oncol Biol Phys 81:e615-22. 2011
  4. ncbi Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 78:735-42. 2010
  5. ncbi Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck
    Roy B Tishler
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 65:1036-44. 2006
  6. ncbi Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer
    Robert Haddad
    Head and Neck Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:4514-23. 2009
  7. ncbi Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach
    Marshall R Posner
    Department of Medical Oncology, Dana Farber Cancer Institute, SW 430, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 31:778-85. 2004
  8. ncbi Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer
    Robert Haddad
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Clin Oncol 28:104. 2005
  9. ncbi Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy
    Xing Qi Lu
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 71:281-9. 2008
  10. ncbi Frameless angiogram-based stereotactic radiosurgery for treatment of arteriovenous malformations
    Xing Qi Lu
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 84:274-82. 2012

Collaborators

Detail Information

Publications17

  1. ncbi Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Int J Radiat Oncol Biol Phys 81:1500-5. 2011
    ..We report the use of SBRT for 60 consecutive patients (81 lesions) who had radiological progressive spine metastasis with epidural involvement after previous radiation for spine metastasis...
  2. ncbi Clinical outcome after hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, MA 02445, USA
    Comput Aided Surg 16:112-20. 2011
    ..The objective of this study was to assess the neurological outcome, local control rate and morbidity associated with a 5-fraction regime of hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors...
  3. ncbi Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Int J Radiat Oncol Biol Phys 81:e615-22. 2011
    ..We therefore retrospectively analyzed a planned strategy of initial chemotherapy with restaging and then treatment for those patients with no evidence of metastatic progression with SBRT...
  4. ncbi Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 78:735-42. 2010
    ..We explored the safety and effectiveness of a 3-day course of hypofractionated stereotactic body radiotherapy (SBRT) followed by gemcitabine in this population...
  5. ncbi Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck
    Roy B Tishler
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 65:1036-44. 2006
    ..In a Phase I/II trial, we investigated concurrent weekly docetaxel and concomitant boost radiation in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) after induction chemotherapy...
  6. ncbi Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer
    Robert Haddad
    Head and Neck Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:4514-23. 2009
    ....
  7. ncbi Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach
    Marshall R Posner
    Department of Medical Oncology, Dana Farber Cancer Institute, SW 430, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 31:778-85. 2004
    ..ST may represent the cutting edge of therapy for patients with curable, locally advanced SCCHN...
  8. ncbi Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer
    Robert Haddad
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Clin Oncol 28:104. 2005
  9. ncbi Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy
    Xing Qi Lu
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 71:281-9. 2008
    ..However, the effect of deformation, defined as any changes in the body and organs relative to the center of fiducials, remains unanswered. This study investigated this problem and a possible solution...
  10. ncbi Frameless angiogram-based stereotactic radiosurgery for treatment of arteriovenous malformations
    Xing Qi Lu
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 84:274-82. 2012
    ..Without DSA as the primary image, target definition may be less than optimal, in some cases precluding the ability to treat with a frameless system. This article reports a novel solution...
  11. ncbi Melanoma brain metastasis: overview of current management and emerging targeted therapies
    Ekokobe Fonkem
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Expert Rev Neurother 12:1207-15. 2012
    ..Additional clinical trials of newer agents involving these pathways are also showing promise. Therefore, targeted therapies must be incorporated into the multimodality management of melanoma brain metastasis...
  12. ncbi Spectral CT with metal artifacts reduction software for improvement of tumor visibility in the vicinity of gold fiducial markers
    Olga R Brook
    Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, 02215, USA
    Radiology 263:696-705. 2012
    ..To evaluate spectral computed tomography (CT) with metal artifacts reduction software (MARS) for reduction of metal artifacts associated with gold fiducial seeds...
  13. ncbi Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base
    Omur Karakoyun-Celik
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    Head Neck 27:353-61. 2005
    ..This approach has led to a 78% rate of organ preservation at 5 years, with a 5% incidence of significant late morbidity (osteonecrosis) that has required medical management...
  14. ncbi Cyberknife radiosurgery for basal skull plasmacytoma
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Neuroimaging 16:361-3. 2006
    ..To our knowledge, this is a first case of successful Cyberknife radiosurgery of a medullary plasmacytoma...
  15. ncbi "Hitting all the right markers to save a life" Solitary fibrous tumors of the central nervous system: Case series and review of the literature
    Ekkehard Kasper
    Division of Neurosurgery, Beth Israel Deaconess Medical Centre, Harvard University, Boston, Massachusetts, USA
    Surg Neurol Int 3:83. 2012
    ..For this reason, we present two cases of large SFTs to illustrate a comprehensive review...
  16. ncbi Safety profile and technical success of imaging-guided percutaneous fiducial seed placement with and without core biopsy in the abdomen and pelvis
    Olga R Brook
    Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    AJR Am J Roentgenol 198:466-70. 2012
    ....
  17. ncbi Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment
    Robert Haddad
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 8:35-44. 2003
    ....